Key Highlights
- Shares rose 0.07% to USD 14.90 on relative Volume of 1.92.
- Third-quarter Revenue was USD 83.7 million, with Net Income of USD 31.7 million.
- Research and development expense rose to USD 16.6 million and is expected to keep rising.
- Nine-month Buybacks were USD 74.9 million, with none in the third quarter.
Aurinia Pharmaceuticals (NASDAQ:AUPH) shares traded at USD 14.90 on November 20, 2026, up 0.07%, with a relative volume at time of 1.92. The company has given no reason for the heavy trading. It completed its Acquisition of Kezar on May 11, 2026 and filed its report for the quarter ended September 30 on October 30, so both events came earlier.
Aurinia is incorporated in Alberta, Canada, and based in Edmonton. It develops therapies for people with autoimmune diseases that have high unmet medical needs. In January 2021 it introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adults with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell-activating Factor and a proliferation-inducing ligand, as a potential autoimmune treatment. Its fiscal year ends on December 31.
The Third Quarter
Net product sales were USD 79.4 million versus USD 70.6 million. License, collaboration and Royalty revenue was USD 4.3 million versus USD 2.8 million, bringing total revenue to USD 83.7 million versus USD 73.5 million.
Cost of revenue was USD 8.3 million versus USD 8.2 million. Selling, general and administrative expense was USD 24.7 million versus USD 26.2 million, while Research and Development expense rose to USD 16.6 million from USD 8.4 million. Income from operations was USD 35.4 million versus USD 29.7 million.
Income tax expense was USD 7.0 million versus USD 0.41 million, and net income was USD 31.7 million versus USD 31.6 million. Earnings Per Share were USD 0.24 basic and USD 0.23 diluted in both periods.
Nine Months
Net product sales were USD 232.4 million versus USD 197.2 million, and total revenue was USD 244.6 million versus USD 205.9 million. Income from operations was USD 123.1 million versus USD 71.7 million. Net income was USD 103.5 million versus USD 76.4 million, or USD 0.76 per diluted share versus USD 0.55. The effective tax rate was 21.3% versus 2.6%, with the remaining deferred tax valuation allowance released in the fourth quarter of 2025.
Balance Sheet, Cash Flow and Buybacks
Cash, cash equivalents and restricted cash were USD 46.1 million versus USD 80.2 million at December 31, 2025, and short-term investments were USD 440.7 million versus USD 317.8 million. Total Assets were USD 825.7 million, total liabilities were USD 168.2 million and shareholders' Equity was USD 657.5 million.
Operating activities provided USD 131.5 million versus USD 90.0 million. Share repurchases were USD 74.9 million versus USD 98.2 million. The Board approved a program of up to USD 150 million in February 2024 and a further USD 150 million in July 2025. No shares were repurchased in the third quarter, against 1.1 million shares for USD 8.8 million a year earlier.
Kezar and Development Spending
The company accounted for the Kezar deal as an asset acquisition, allocating assets and liabilities on May 11, 2026 on a relative Fair Value basis. It acquired USD 5.2 million of net cash and cash equivalents and paid USD 3.7 million of Net Cash Excess CVR to legacy Kezar shareholders.
Higher research and development expense came mainly from more employees dedicated to research and development, clinical Manufacturing and supply, and other costs as programs advance. The company expects the expense to keep increasing.
What to Watch Next for Aurinia
The company has given no reason for the November 20 volume, and its results were reported earlier. The reported record shows rising product sales, steady profit, a larger Investment balance and a pause in buybacks during the quarter. Development spending and any resumption of repurchases are the points to follow.






Please wait processing your request...